SAFETY AND TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B

被引：0
|
作者：
Lampertico, Pietro [1 ]
Vigano, Mauro [1 ]
Di Costanzo, Giovan Giuseppe [2 ]
Sagnelli, Evangelista [3 ]
Fasano, Massimo [4 ]
Di Marco, Vito [5 ]
Boninsegna, Sara [6 ]
Farci, Patrizia [7 ]
Fargion, Silvia [8 ]
Giuberti, Tiziana [9 ]
Iannacone, Claudio [10 ]
Massetto, Benedetta [11 ]
Martins, Eduardo B. [12 ]
Colombo, Massimo [1 ]
机构：
[1] Univ Milan, Div Gastroenterol 1, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[2] Cardarelli Hosp, Liver Unit, Naples, Italy
[3] SS Anna & Sebastiano Hosp, Infect Dis Unit, Caserta, Italy
[4] Univ Bari, Clin Infect Dis, Bari, Italy
[5] Univ Palermo, Gastroenterol & Hepatol Unit, Di Bi MIS, Palermo, Italy
[6] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy
[7] Univ Cagliari, Dept Med Sci, Monserrato, Italy
[8] Univ Milan, Dept Internal Med, IRCCS Fdn Policlin, Milan, Italy
[9] Azienda Osped Univ Parma, Unit Infect Dis & Hepatol, Parma, Italy
[10] SPARC Consulting, Milan, Italy
[11] Roche, Monza, Italy
[12] Genentech Inc, San Francisco, CA 94080 USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
135
引用
收藏
页码：387A / 387A
页数：1
相关论文
共 50 条
  • [1] The cost effectiveness analysis of treatment with peginterferon alfa-2a (40KD) in patients with hbeag-negative chronic hepatitis B
    Kowalik, E.
    Niewada, M.
    Jakubczyk, M.
    Horban, A.
    Berak, H.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A300 - A300
  • [2] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [3] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-NEGATIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-debek, M.
    Russel-Szymczyk, M.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A277 - A277
  • [4] EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D-PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B
    Lampertico, P.
    Vigano, M.
    Di Costanzo, G.
    Sagnelli, E.
    Fasano, M.
    Di Marco, V.
    Boninsegna, S.
    Farci, P.
    Fargion, S.
    Giuberti, T.
    Iannacone, C.
    Massetto, B.
    Fedeli, P.
    Colombo, M.
    [J]. JOURNAL OF HEPATOLOGY, 2010, 52 : S45 - S45
  • [5] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    [J]. HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [6] HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Drakoulis, C.
    Bakalos, G.
    Papatheodoridis, G.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S286 - S287
  • [7] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
    Caruntu, Florin Alexandru
    Streinu-Cercel, Adrian
    Gheorghe, Liliana Simona
    Grigorescu, Mircea
    Sporea, Ioan
    Stanciu, Carol
    Andronescu, Dan
    Voinea, Florea
    Diculescu, Mircea
    Oproiu, Alexandru
    Voiosu, Rodu
    [J]. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
  • [8] Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment
    Jia, Ji-Dong
    Piratvisuth, Teerha
    Lau, George K. K.
    Luo, Kang-Xian
    Jin, Rui
    Lu, Zhi-Meng
    Marcellin, Patrick
    Popescu, Matei
    Button, Peter
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A88 - A88
  • [9] Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis
    Boglione, Lucio
    Cariti, Giuseppe
    Ghisetti, Valeria
    Burdino, Elisa
    Di Perri, Giovanni
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (06) : 1047 - 1052
  • [10] PEGINTERFERON ALFA-2A [40KD] PLUS ADEFOVIR FOR 96 WEEKS IN HBEAG-NEGATIVE CHB RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION
    Cao, Z.
    Yu, H.
    Ma, L.
    Zhang, Y.
    Liu, Y.
    Ma, B.
    Wu, H.
    Chen, X.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S283 - S283
12345